News
FIT Portfolio
fit.uni-tuebingen.de
Benjamin Weide, Claus Garbe. Novartis - COMBI-r, Studiencode: CDRB436BDE Claus Garbe. Novartis Pharma GmbH. Studie CA
DKTK: Je mehr Mutationen im Tumor, desto wirksamer die Immuntherapie
www.dkfz.de
... Simone M. Goldinger, Jochen Utikal, Jessica C. Hassel, Benjamin Weide, Katharina C. Kaehler, Carmen Loquai, Peter Mohr, Ralf Gutzmer, ...
Cancer Bio-Immunotherapy in Siena Nibit Meeting
www.sienameeting-nibit.org
Cancer Bio-Immunotherapy in Siena Nibit Meeting
sorted by relevance / date